Array Biopharma Inc (NASDAQ:ARRY) shares traded 2.09% up during most recent session to reach at the closing price of $8.32. The stock exchanged hands 3.2 Million shares versus average trading capacity of 4.2 Million shares, yielding a market cap of $1.42 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $11.75 within the next 52-weeks. The mean target projections are based on 8 opinions.
Taking a broader look brokerage firms’ analysts on the street with an expectant view have Array Biopharma Inc (NASDAQ:ARRY) high price target of $14 and with a conservative view have low price target of $9.
JP Morgan “Upgrades” Array Biopharma Inc (NASDAQ:ARRY) in a research note issued to investors on 5/03/17 to Overweight with price target of $0.
Additionally on 2/03/17 JP Morgan “Downgrades” Array Biopharma Inc (NASDAQ:ARRY) to Neutral setting price target0 and on 1/30/17 Leerink Swann “Downgrades” the stock to Market Perform0. Furthermore on 11/04/16 Cowen & Co. “Initiates Coverage On” the stock to Outperform.
On the other hand the company has Relative Strength Index (RSI 14) of 49.03 along with Average True Range (ATR 14) of 0.55, Consequently Array Biopharma Inc (NASDAQ:ARRY)’s weekly and monthly volatility is 8.80%, 6.32% respectively. The company’s beta value is at 2.25.
In terms of Buy, Sell or Hold recommendations, Array Biopharma Inc (NASDAQ:ARRY) has analysts’ mean recommendation of 1.8. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
Analysts who have weighed in on projected earnings growth are expecting that Array Biopharma Inc (NASDAQ:ARRY) will report earnings of $-0.22 for the current quarter on or around 8/3/17, however the company’s high EPS estimates are $-0.01 and low estimates are $-0.29. However the company reported $-0.17 earnings per share for the same quarter during last year.
Previously Array Biopharma Inc (NASDAQ:ARRY) reported $-0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.16 by $-0.05. The company posted an earnings surprise of -31.2%.
Array Biopharma Inc (NASDAQ:ARRY)’s revenue estimates for the current quarter are $28.61 Million according to 9 number of analysts, for the current quarter the company has high revenue estimates of $37 Million in contradiction of low revenue estimates of $13 Million. For the current year the company’s revenue estimates are $142.71 Million compared to low analyst estimates of $130.1 Million and high estimates of $150.4 Million according to 9 number of analysts.
Currently Array Biopharma Inc (NASDAQ:ARRY)’s shares owned by insiders are 0.2%, whereas shares owned by institutional owners are 92.2%. However the six-month change in the insider ownership was recorded -17.16%, as well as three-month change in the institutional ownership was recorded 5.02%.
Array Biopharma Inc (NASDAQ:ARRY) 52-week high price stands13.40 and low price stands2.70, its price distance from 52-week high is -37.91% while its distance from 52-week low price is 208.15%. The stock hit its 52-week high on 02/10/17, and 52-week low on 05/16/16.
Array Biopharma Inc (NASDAQ:ARRY)’s trailing twelve month revenues are $160.3 Million, whereas its price to sales ratio for the same period is 8.77. Its book value per share for the most recent quarter is $0.16 while its price to book ratio for the same period is 52, as for as the company’s cash per share for the most recent quarter is $1.22, however its price to cash per share ratio for the same period is 6.8. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.